KMT2D and nonpapillary renal cell carcinoma: In our study, mutations in VHL, PBRM1, BAP1, and SERD2 can reach 74%, 50%, 24%, and 18%, respectively, for ccRCC patients; while for nccRCC patients, the most frequent mutation was FH (29%), MLH3 (24%), ARID1A (18%), KMT2D (18%) and CREBBP (18%).